Prelude Therapeutics Incorporated PRLD
Set alert
3.84 USD 0.00 0.00%
As of Nov 3, 2:06 PM ET
3.83 Day range 4.00
1.17 52-week range 6.83
- YTD
- +32.41%
- 1 year
- -3.52%
- Open
- 3.87
- Prev close
- 3.84
- Mkt cap
- 304.64M
- Vol
- 76.64K
- Avg vol
- 492.23K
- EPS
- -0.73
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.83
- High
- 4.00
- Forward P/E
- -0.82
- Beta
- 1.55
- Short ratio
- 7.51
- Inst. own
- 84.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 1.23
- 200-d avg
- 3.50
- 1y target
- 5.00
Analyst view
Consensus: hold
Hold
Price target (mean) 5.00 +30.2% upside
Now 3.84
- Target (low)
- 1.00
- Target (mean)
- 5.00
- Target (high)
- 10.00
Ratings (0m) 5 3 buy · 0 hold · 2 sell
- Strong buy2
- Buy1
- Hold0
- Sell1
- Strong sell1
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.46725 | -0.48 – -0.44 | -0.45 | -3.8% | 0 | 0.0% | 4 |
| Next quarter | -0.44333 | -0.48 – -0.38 | -0.42 | -5.5% | 0 | 0.0% | 3 |
| Current year | -1.77 | -1.78 – -1.77 | -2.02 | +12.1% | 1.50M | 0.0% | 4 |
| Next year | -1.50 | -2.03 – -0.676 | -1.77 | +15.7% | 0 | -100.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Nov 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 28, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Sep 16, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Sep 16, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Sep 10, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Aug 15, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Mar 13, 2024 | JMP Securities | Initiated | — | Market Outperform |
| Feb 20, 2024 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Dec 19, 2023 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
| Nov 7, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 19, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 17, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 4, 2023 | Morgan Stanley | Reiterated | Equal-Weight | Equal-Weight |
| Aug 4, 2023 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Mar 17, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 21, 2022 | B of A Securities | Downgrade | Neutral | Underperform |
| Nov 17, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 15, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| Sep 9, 2022 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Jul 29, 2022 | Jefferies | Initiated | — | Buy |
| May 12, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 17, 2022 | Morgan Stanley | Maintained | — | Overweight |
| Mar 15, 2022 | B of A Securities | Downgrade | Buy | Neutral |
| Feb 28, 2022 | Barclays | Downgrade | Overweight | Equal-Weight |
| Nov 17, 2021 | Barclays | Maintained | — | Overweight |
| Oct 11, 2021 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Oct 8, 2021 | Barclays | Maintained | — | Overweight |
| Jul 27, 2021 | B of A Securities | Upgrade | Neutral | Buy |